Malignant germ cell tumors in childhood

Area of Science:

• Pediatric Oncology
• Medical Chemotherapy
• Tumor Biology

Background:

• Germ cell tumors (GCTs) historically had a poor prognosis before effective chemotherapy.
• Multiagent chemotherapy has revolutionized GCT treatment outcomes.
• Assessing treatment efficacy in pediatric GCT patients is crucial for improving survival.

Purpose of the Study:

• To evaluate the effectiveness of multiagent chemotherapy in children diagnosed with germ cell tumors.
• To compare the outcomes of two distinct chemotherapy regimens: PVB-M and BEP.
• To determine the superior chemotherapy regimen for advanced pediatric germ cell tumors.

Main Methods:

• A retrospective analysis of 107 pediatric patients diagnosed with germ cell tumors between 1984 and 1990.
• Postsurgical therapy decisions were based on tumor site, stage, and histology.
• Patients received either cisplatin, vinblastin, bleomycin, and methotrexate (PVB-M) from 1984-1988 or bleomycin, etoposide, and cisplatin (BEP) from 1988-1990.

Main Results:

• The BEP regimen achieved a 85% complete remission rate compared to 40% for the PVB-M regimen.
• Overall survival at 3 years was 80% for BEP, versus 30% at 5 years for PVB-M.
• BEP demonstrated superior efficacy and potentially reduced toxicity and improved compliance in children.

Conclusions:

• The combination of bleomycin, etoposide, and cisplatin (BEP) is more effective than cisplatin, vinblastin, bleomycin, and methotrexate (PVB-M) for treating advanced pediatric germ cell tumors.
• Etoposide with cisplatin offers greater efficacy, decreased toxicity, and better compliance in children with GCTs.
• The findings support BEP as a preferred chemotherapy regimen for this patient population.